References
- RazDJZellJAOuSHGandaraDRAnton-CulverHJablonsDMNatural history of stage I non-small cell lung cancer: implications for early detectionChest2007132119319917505036
- GoulartBHReyesCMFedorenkoCRReferral and treatment patterns among patients with stages III and IV non-small-cell lung cancerJ Oncol Pract201391425023633970
- SmallACTsaoCKMoshierELPrevalence and characteristics of patients with metastatic cancer who receive no anticancer therapyCancer2012118235947595422707387
- IslamKMJiangXAnggondowatiTLinGGantiAKComorbidity and survival in lung cancer patientsCancer Epidemiol Biomarkers Prev20152471079108526065838
- TammemagiCMNesulund-DudasCSimoffMKvalePImpact of comorbidity on lung cancer survivalInt J Cancer2003103679280212516101
- GroseDDevereuxGMilroyRComorbidity in lung cancer: important but neglected. a review of the current literatureClin Lung Cancer201112420721121726818
- EdwardsBKNooneAMMariottoABAnnual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancerCancer201412091290131424343171
- KlabundeCNPotoskyALLeglerJMWarrenJLDevelopment of a comorbidity index using physician claims dataJ Clin Epidemiol200053121258126711146273
- LuchtenborgMJakobsenEKrasnikMLinklaterKMMellemgaardAMøllerHThe effect of comorbidity on stage-specific survival in resected non-small cell lung cancer patientsEur J Cancer201248183386339522795582
- MellemgaardALuchtenborgMIachinaMRole of comorbidity on survival after radiotherapy and chemotherapy for nonsurgically treated lung cancerJ Thorac Oncol201510227227925371078
- NalbantovGKietselaerBVandecasteeleKCardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patientsRadiother Oncol2013109110010624044794
- ZhaiRYuXShaferAWainJCChristianiDCThe impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resectionChest2014145234635324008835
- LeeSJLeeJParkYSImpact of chronic obstructive pulmonary disease on the mortality of patients with non-small-cell lung cancerJ Thorac Oncol20149681281724807154
- GadgeelSMKalemkerianGPRacial differences in lung cancerCancer Metastasis Rev2003221394612716035
- PatelJDSocinskiMAGaronEBPointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerJ Clin Oncol201331344349435724145346
- BarlesiFScherpereelAGorbunovaVMaintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trialAnn Oncol20142551044105224585722
- ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543345118506025
- ZhouCWuYLChenGFinal overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Ann Oncol20152691877188326141208
- RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168